Clinical Trial Update: Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating venetoclax with hypomethylating agents and subcutaneous cytarabine in patients with CEBPA-mutated acute myeloid leukemia, including…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• CYTARABINE (CYTARABINE)
• Venetoclax (venetoclax)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Acute Myeloid Leukemia (AML), CEBPA Mutation | Phase 1, Phase 2 | Status: RECRUITING